Regeneus (ASX:RGS) - CEO, Karolis Rosickas
CEO, Karolis Rosickas
Source: LOGIN Conferences
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clinical-stage regenerative medicine company Regeneus (RGS) has appointed Karolis Rosickas as CEO, following the resignation of Leo Lee
  • Karolis has over 15 years of experience in healthcare, technology and finance
  • Most recently, he was CEO and Co-Founder for a nutrition technology business, OME Health
  • The former CEO resigned to take on a new  role in a major Japanese pharmaceutical company, however, Leo will remain with Regeneus as a Non-Executive Director
  • Shares in Regeneus closed 7.41 per cent lower, at 12.5 cents

Regeneus (RGS), has appointed Karolis Rosickas as CEO, following the resignation of Leo Lee.

Karolis has more than 15 years’ experience across healthcare, technology and finance businesses.

Prior to his appointment, he was CEO and Co-Founder for a nutrition technology business, OME Health. He also co-founded SingCell, a stem cell contract development and manufacturing organisation.

Mr Rosickas had previously held senior positions with investment banking company HSBC, JP Morgan, KPMG and multinational food-products corporation, Danone.

He is a certified chartered financial analyst and with a Masters in Business Administration.

Regeneus Independent Chairman Barry Sechos said Karolis’ appointment would be a significant step for the company’s growth.

“His experience in the healthcare and finance sectors will be invaluable for the company, furthermore, his experience as a Co-Founder of an organisation dedicated to stem cell development and manufacturing will be critical for Regeneus’ next phase of growth,” he said.

“We thank Leo for his service and are delighted that the company will continue to benefit from his strategic guidance as a Non-Executive Director,” he added.

Meanwhile, Leo Lee has resigned as CEO of the company for a new role in a major Japanese pharmaceutical company. He’ll remain on the Regeneus board as a Non-Executive Director.  

Shares in Regeneus closed 7.41 per cent lower, at 12.5 cents. 

RGS by the numbers
More From The Market Herald
Argenica Therapeutics (ASX:AGN) - CEO, Dr Liz Dallimore

" Argenica Therapeutics (ASX:AGN) determines safe starting dose level for ARG-007

Argenica Therapeutics (ASX:AGN) determines safe starting dose level from toxicology and genotoxicity studies
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) to raise $6m for cell therapies

Arovella Therapeutics (ASX:ALA) has received firm commitments from institutional and sophisticated investors for a $4.57 million…

" Radiopharm Theranostics (ASX:RAD) acquires IP ownership of Radiopharmaceutical Nanobodies

Radiopharm Theranostics (ASX:RAD) acquires full intellectual property (IP) ownership to three assets from NanoMab Technology.
Nuheara (ASX:NUH) - CEO, Justin Miller

" Nuheara (ASX:NUH) completes $1.06m SPP

Hearing technology company Nuheara (ASX:NUH) has completed its share purchase plan (SPP) with applications totalling $1,067,200.